Mustophoran (Fotemustine)

Fotemustine works by adding alkyl groups to DNA, creating cross‑links that prevent DNA replication and transcription. This damage triggers cell‑cycle arrest and programmed cell death, preferentially affecting rapidly dividing cancer cells while sparing most normal tissues.

The dosing regimen for Mustophoran is determined by the treating oncologist based on the patient’s condition, body surface area, and clinical response. Physicians calculate the appropriate intravenous dose and schedule according to established oncology protocols.

Fotemustine is classified as contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception. Breastfeeding is not recommended, as the drug may be excreted in milk and affect the infant.

To order Mustophoran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mustophoran (fotemustine) is similar to other nitrosoureas such as carmustine and lomustine in its mechanism of DNA alkylation, but it is formulated for intravenous use and has a distinct pharmacokinetic profile that may offer different efficacy and toxicity patterns, especially in melanoma and high‑grade glioma.

Mustophoran should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and extreme temperatures. Do not freeze. Follow standard aseptic handling procedures for intravenous solutions.

Mustophoran is given as an intravenous infusion under the supervision of qualified healthcare professionals. The infusion rate and duration are set by the prescribing oncologist and nursing staff, typically in a controlled clinical setting to monitor for immediate reactions.

The most serious risks include severe bone‑marrow suppression leading to infection or bleeding, pulmonary fibrosis, acute liver failure, and life‑threatening allergic reactions. Patients should be closely monitored for signs of infection, respiratory difficulty, jaundice or rash during treatment.

Mustophoran is contraindicated in patients with known hypersensitivity to fotemustine or other nitrosoureas, in those with severe bone‑marrow failure, uncontrolled liver disease, or active pulmonary fibrosis. It should also be avoided in pregnant women and in individuals who cannot receive intravenous therapy.